modernretina.com

Website review modernretina.com

Modern Retina – Ophthalmology News, Events & Expert Insights

 Generated on March 31 2026 15:12 PM

Old data? UPDATE !

The score is 57/100

SEO Content

Title

Modern Retina – Ophthalmology News, Events & Expert Insights

Length : 60

Perfect, your title contains between 10 and 70 characters.

Description

Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal care to improve patient outcomes.

Length : 155

Great, your meta description contains between 70 and 160 characters.

Keywords

Very bad. We haven't found meta keywords on your page. Use this free online meta tags generator to create keywords.

Og Meta Properties

Good, your page take advantage of Og Properties.

Property Content
title Modern Retina
type website
image https://www.modernretina.com/MR_Hover_Logo.jpg
url https://www.modernretina.com/
image:url https://www.modernretina.com/MR_Hover_Logo.jpg
image:width 1200
image:height 630
image:alt Modern Retina – Ophthalmology News, Events & Expert Insights

Headings

H1 H2 H3 H4 H5 H6
1 56 46 4 16 0
  • [H1] Latest News
  • [H2] Conference Coverage
  • [H2] Trending on Modern Retina
  • [H2] Shorts
  • [H2] Podcasts
  • [H2] Videos
  • [H2] Modern Retina Digital Edition
  • [H2] Continuing Medical Education
  • [H2] (CME Track) Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments
  • [H2] (CME Track) Expanding Horizons in Toric IOLs: Translating Technological Advances Into Improved Patient Outcomes
  • [H2] (CME Track) The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery
  • [H2] (COPE Credit) Time Matters in GA: The Impact of Early Detection and Proactive Treatment Approaches
  • [H2] (CME Track) Visionary Approaches: Rethinking Therapeutic and Interventional Glaucoma Management
  • [H2] (CME Credit) Time Matters in GA: The Impact of Early Detection and Proactive Treatment Approaches
  • [H2] (CME Track) The TED Perspective: A Multidisciplinary Approach to Thyroid Eye Care
  • [H2] (COPE Track) Patient-Centered Treatment Strategies in the Management of nAMD and DME
  • [H2] (CME Track) Patient-Centered Treatment Strategies in the Management of nAMD and DME
  • [H2] Practical Approaches to Modern Dry Eye Treatment and Management
  • [H2] (COPE Track) Visionary Approaches: Rethinking Therapeutic and Interventional Glaucoma Management
  • [H2] (COPE Track) Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments
  • [H2] (COPE Track) Expanding Horizons in Toric IOLs: Translating Technological Advances Into Improved Patient Outcomes
  • [H2] (COPE Track) The TED Perspective: A Multidisciplinary Approach to Thyroid Eye Care
  • [H2] (COPE Track) The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery
  • [H2] 20th Annual Controversies in Modern Eye Care
  • [H2] (CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments
  • [H2] (COPE Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments
  • [H2] (CME Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME
  • [H2] (COPE Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME
  • [H2] Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience
  • [H2] (CME Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation
  • [H2] Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience
  • [H2] (COPE Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation
  • [H2] Collaborative Care Symposium
  • [H2] Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge
  • [H2] (CME Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes
  • [H2] (COPE Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes
  • [H2] (CME Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management
  • [H2] (COPE Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management
  • [H2] (CME Track) Toric IOLs Unleashed: From Technological Progress to Patient Success
  • [H2] (COPE Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR
  • [H2] (COPE Track) Toric IOLs Unleashed: From Technological Progress to Patient Success
  • [H2] (COPE Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD
  • [H2] (CME Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD
  • [H2] (CME Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR
  • [H2] Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop
  • [H2] (COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care
  • [H2] (COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care
  • [H2] (CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care
  • [H2] (CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care
  • [H2] Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease
  • [H2] Interventional Dry Eye: A Stepwise Treatment & Management Approach
  • [H2] (CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease
  • [H2] (CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management
  • [H2] (CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment
  • [H2] (CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice
  • [H2] (CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP
  • [H2] All News
  • [H3] Aflibercept to treat ROP in extremely-low-birth-weight children
  • [H3] Multi-luminance shape discrimination test shows reliability in low-vision RP population
  • [H3] Aflibercept to treat ROP in extremely-low-birth-weight children
  • [H3] Eichenbaum Acorns: Collaborative retina care with Jeffry D. Gerson, OD, FAAO
  • [H3] Eichenbaum Acorns: Mentorship, momentum, and the making of a retina podcast
  • [H3] Eichenbaum Acorns: Inside the mindset of an early adopter with Jordan M. Graff, MD, FACS
  • [H3] The Retina TL;DR: Redefining office-based surgery for retina care with Jonathan Feistmann, MD
  • [H3] Eichenbaum Acorns: A leadership conversation with Rishi P. Singh, MD, FASRS, on advancing CME
  • [H3] The Retina TL;DR: Rethinking retinal detachment repair with Tony Stefater, MD, PhD; and Tommy Stryjewski, MD
  • [H3] PHOTON Trial Outcomes: Impact on DME Patient Care in Clinical Practice
  • [H3] PULSAR Study Findings: Implications for Treating nAMD in Clinical Practice
  • [H3] Integrating AI to manage DR in a primary care setting
  • [H3] What to expect from virtual AAO 2020
  • [H3] Genetic Retinoblastoma Risk Stratified by Age Among Patients with Metachronous Bilateral Conversion
  • [H3] Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open Innovation
  • [H3] Ophthalmic drug shortages more frequent, longer lasting than average
  • [H3] Johnson & Johnson’s TECNIS PureSee EDOF IOL cleared for US market
  • [H3] Eichenbaum Acorns: Collaborative retina care with Jeffry D. Gerson, OD, FAAO
  • [H3] NovaBridge, Visara report positive phase 2a results for dual VEGF-A/ANG-2 inhibitor VIS-101
  • [H3] FDA clears phase I/II trial of SVT-001 cell therapy for familial drusen–associated vision loss
  • [H3] Ocugen completes enrollment in liMeliGhT phase 3 trial of OCU400 for retinitis pigmentosa
  • [H3] Pegcetacoplan Does Not Impact Anti-VEGF Treatment in Geographic Atrophy, With Ted Leng, MD, MS
  • [H3] Q&A: AI-predicted retinal function shows promise in geographic atrophy
  • [H3] Dr. Mali’s top 5 predictions in ophthalmology for 2026
  • [H3] The Retina TL;DR with Dr. Weng: Tracking retinal gene therapies with Arshad M. Khanani, MD, MA, FASRS
  • [H3] Q&A: Gennady Landa, MD, shares clinical insights on the ranibizumab ocular implant
  • [H3] Samsung Bioepis reaches settlement agreement for Eylea (aflibercept) biosimilar
  • [H3] ISS 2026 highlights advances in ophthalmic imaging for retinal practice
  • [H3] American College of Physicians policy paper urges medical community to drop the term “'provider"
  • [H3] PRIMA System: A major step in the battle against GA
  • [H3] MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio
  • [H3] Metformin use associated with reduced incidence of intermediate AMD
  • [H3] FDA decision: Carbachol–brimonidine ophthalmic solution approved for presbyopia following BRIO phase 3 results
  • [H3] New optoretinography technique allows direct measurement of rod function in vivo
  • [H3] Navigating geographic atrophy from biomarkers to bilateral therapy
  • [H3] Ollin Biosciences reports positive head-to-head phase 1b data for OLN324 vs faricimab
  • [H3] Eichenbaum Acorns: Mentorship, momentum, and the making of a retina podcast
  • [H3] Long-lived Greenland sharks may point to new approaches for retinal disease
  • [H3] Molecular insights and clinical experience: Extending anti-VEGF durability
  • [H3] Q&A: Evolving approaches to geographic atrophy management
  • [H3] Nanoscope secures new US patent for Multi-Characteristic Opsin (MCO) technology platform
  • [H3] Rates of retinal layer thinning predict visual field progression in glaucoma
  • [H3] First patient treated in dose-expansion portion of SpliceBio's phase 1/2 ASTRA clinical trial
  • [H3] FDA grants Fast Track Designation to Complement Therapeutics’ CTx001 for geographic atrophy
  • [H3] 8 things to know about aflibercept 8 mg for retinal vascular disease
  • [H3] A new treatment round-up for AMD and GA
  • [H4] Multi-luminance shape discrimination test shows reliability in low-vision RP population
  • [H4] Phase 2 topline data: Ocugen OCU410 reduces geographic atrophy lesion growth by 31% at 12 months
  • [H4] The Retina TL;DR with Dr. Weng: Moving beyond anti-VEGF with OTX-TKI and Pravin U. Dugel, MD
  • [H4] ONL Therapeutics randomizes first European patient in phase 2 GA trial of Xelafaslatide
  • [H5] The Retina TL;DR with Dr. Weng: Moving beyond anti-VEGF with OTX-TKI and Pravin U. Dugel, MD
  • [H5] Pegcetacoplan Does Not Impact Anti-VEGF Treatment in Geographic Atrophy, With Ted Leng, MD, MS
  • [H5] The Retina TL;DR with Dr. Weng: Tracking retinal gene therapies with Arshad M. Khanani, MD, MA, FASRS
  • [H5] Exploring Emerging Therapies in the Retinal Vascular Disease Pipeline
  • [H5] The Retina TL;DR with Dr. Weng: Targeting the Fas signaling pathway with David Zacks, MD, PhD
  • [H5] Evaluating Safety and Clinical Confidence between Aflibercept 8 mg and 2 mg in Retinal Vascular Diseases
  • [H5] Management Approaches for Suboptimal Responders in AMD, DME, and RVO
  • [H5] Comparing Aflibercept 8 mg and Faricimab in RVO
  • [H5] Insights from Privotal Trials for Aflibercept (8 mg) in RVO
  • [H5] Evaluating Retinal Drying, Durability and IOP Management with Second-Generation Anti-VEGF Therapies in Retinal Vascular Diseases
  • [H5] Loading Dose Adjustments and Treatment Switching Strategies in Retinal Vascular Diseases
  • [H5] Enhancing Durability and Fluid Control with Aflibercept 8 mg in Retinal Vascular Diseases
  • [H5] Evolving Therapeutic Strategies with Next-Generation Anti-VEGF Agents in Retinal Vascular Diseases
  • [H5] Clinical Insights Shaping Real-World Decision-Making in Geographic Atrophy
  • [H5] Managing Geographic Atrophy in a 90-Year-Old Patient with Coexisting Neovascular AMD and Recurrent CNV Activation
  • [H5] Evaluating Progressive Multifocal Geographic Atrophy in an Asymptomatic 81-Year-Old Male

Images

We found 135 images on this web page.

23 alt attributes are empty or missing. Add alternative text so that search engines can better understand the content of your images.

Text/HTML Ratio

Ratio : 3%

This page's ratio of text to HTML code is below 15 percent, this means that your website probably needs more text content.

Flash

Perfect, no Flash content has been detected on this page.

Iframe

Great, there are no Iframes detected on this page.

URL Rewrite

Good. Your links looks friendly!

Underscores in the URLs

Perfect! No underscores detected in your URLs.

In-page links

We found a total of 89 links including 0 link(s) to files

Anchor Type Juice
All News Internal Passing Juice
Blogs Internal Passing Juice
All Videos Internal Passing Juice
Case-Based Roundtable Series Internal Passing Juice
Eichenbaum Acorns Internal Passing Juice
Expert Interviews Internal Passing Juice
Eyeviews Internal Passing Juice
Insights Internal Passing Juice
Medical World News External Passing Juice
Podcasts Internal Passing Juice
Rapid Readouts Internal Passing Juice
The Retina TL;DR Internal Passing Juice
Viewpoints Internal Passing Juice
Conference Coverage Internal Passing Juice
Conference Listing Internal Passing Juice
Modern Retina Digital Edition Internal Passing Juice
Supplements And Featured Publications Internal Passing Juice
Between the Lines Internal Passing Juice
CME/CE Internal Passing Juice
EYLEA 8mg for nAMD and DME Treatment Internal Passing Juice
Sponsored Resources Internal Passing Juice
Partners Internal Passing Juice
Subscribe Internal Passing Juice
AMD Internal Passing Juice
Wet AMD Internal Passing Juice
Biosimilar Internal Passing Juice
Diabetic Macular Edema Internal Passing Juice
Diabetic Eye Awareness Internal Passing Juice
Diabetic Retinopathy Internal Passing Juice
Geographic Atrophy Internal Passing Juice
Imaging Internal Passing Juice
Inherited Retinal Diseases Internal Passing Juice
Ophthalmology Internal Passing Juice
RVO Internal Passing Juice
Retina Technology Internal Passing Juice
Retinal Surgery Internal Passing Juice
Uveitis Internal Passing Juice
Geographic Atrophy Internal Passing Juice
ISS 2026 highlights advances in ophthalmic imaging for retinal practice Internal Passing Juice
FLORetina: Inadvertent anti-VEGF interval increases during the COVID-19 pandemic Internal Passing Juice
Treating MacTel: First identify patient candidates and appropriate eye selection Internal Passing Juice
A medical fellow finds some magic at the AAO Annual Meeting Internal Passing Juice
FLORetina 2025: EU-ROP Registry bridges borders for real-world insight Internal Passing Juice
FLORetina 2025: Updates on tinlarebant in adolescent Stargardt disease Internal Passing Juice
FLORetina 2025: Long-term follow-up in pediatric gene therapy Internal Passing Juice
FLORetina 2025: Mary Elizabeth Hartnett on ROP research and risk management Internal Passing Juice
FLORetina 2025: Reframing retinal disease through the lens of choroidal health Internal Passing Juice
FLORetina 2025: Antithrombotic use examined in wet AMD submacular hemorrhage Internal Passing Juice
Martin David Harp Internal Passing Juice
Christina Y. Weng, MD, MBA, FASRS Internal Passing Juice
View All Internal Passing Juice
Eichenbaum Acorns: Collaborative retina care with Jeffry D. Gerson, OD, FAAO Internal Passing Juice
Eichenbaum Acorns: Mentorship, momentum, and the making of a retina podcast Internal Passing Juice
Eichenbaum Acorns: Inside the mindset of an early adopter with Jordan M. Graff, MD, FACS Internal Passing Juice
The Retina TL;DR: Redefining office-based surgery for retina care with Jonathan Feistmann, MD Internal Passing Juice
Eichenbaum Acorns: A leadership conversation with Rishi P. Singh, MD, FASRS, on advancing CME Internal Passing Juice
The Retina TL;DR: Rethinking retinal detachment repair with Tony Stefater, MD, PhD; and Tommy Stryjewski, MD Internal Passing Juice
PHOTON Trial Outcomes: Impact on DME Patient Care in Clinical Practice Internal Passing Juice
PULSAR Study Findings: Implications for Treating nAMD in Clinical Practice Internal Passing Juice
Integrating AI to manage DR in a primary care setting Internal Passing Juice
What to expect from virtual AAO 2020 Internal Passing Juice
View More Internal Passing Juice
Navigating geographic atrophy from biomarkers to bilateral therapy Internal Passing Juice
8 things to know about aflibercept 8 mg for retinal vascular disease Internal Passing Juice
Inside the mindset of an early adopter Internal Passing Juice
Challenges for young physicians treating patients with GA Internal Passing Juice
AAO highlight: Looking ahead to 2026 Internal Passing Juice
How AI is reshaping ophthalmology in 2025 and beyond Internal Passing Juice
Seeing the difference: Multimodal imaging for AMD and GA Internal Passing Juice
Ryan Livingston Internal Passing Juice
Lynda Charters Internal Passing Juice
Kevin Kunzmann Internal Passing Juice
Jeffry D. Gerson, OD, FAAO Internal Passing Juice
Theodore Leng, MD, MS Internal Passing Juice
Sheryl Stevenson Internal Passing Juice
Joshua Mali, MD Internal Passing Juice
Arshad M. Khanani, MD, MA, FASRS Internal Passing Juice
Modern Retina Staff Reports Internal Passing Juice
Jayanth Sridhar, MD Internal Passing Juice
Matt Hoffman Internal Passing Juice
Sheila Setork, OD Internal Passing Juice
About Internal Passing Juice
Advertise Internal Passing Juice
Editorial Internal Passing Juice
Contact Us Internal Passing Juice
Terms and Conditions Internal Passing Juice
Privacy Internal Passing Juice
Do Not Sell My Personal Information External Passing Juice
Home Internal Passing Juice

SEO Keywords

Keywords Cloud

cope retinal view faao more management fasrs video track cme

Keywords Consistency

Keyword Content Title Keywords Description Headings
more 64
view 52
video 44
track 35
faao 24

Usability

Url

Domain : modernretina.com

Length : 16

Favicon

Great, your website has a favicon.

Printability

We could not find a Print-Friendly CSS.

Language

Good. Your declared language is en.

Dublin Core

This page does not take advantage of Dublin Core.

Document

Doctype

HTML 5

Encoding

Perfect. Your declared charset is UTF-8.

W3C Validity

Errors : 0

Warnings : 0

Email Privacy

Warning! At least one email address has been found in the plain text. Use free antispam protector to hide email from spammers.

Deprecated HTML

Great! We haven't found deprecated HTML tags in your HTML.

Speed Tips

Excellent, your website doesn't use nested tables.
Too bad, your website is using inline styles.
Great, your website has few CSS files.
Too bad, your website has too many JS files (more than 6).
Perfect, your website takes advantage of gzip.

Mobile

Mobile Optimization

Apple Icon
Meta Viewport Tag
Flash content

Optimization

XML Sitemap

Great, your website has an XML sitemap.

https://www.modernretina.com/sitemap.xml
https://www.modernretina.com/sitemap-news.xml

Robots.txt

https://modernretina.com/robots.txt

Great, your website has a robots.txt file.

Analytics

Great, your website has an analytics tool.

   Google Analytics

PageSpeed Insights

Device
Categories

Free SEO Testing Tool

Free SEO Testing Tool is a free SEO tool which provides you content analysis of the website.